AN

Akhila Narayan Nambilithodi Ponnumani

Active Director Director DIN 10557558
DIN 10557558 First appointment Mar 2024
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Akhila Narayan Nambilithodi Ponnumani

Data last updated:

Akhila Narayan Nambilithodi Ponnumani is a Director at Drug Dash Medtech Private Limited (since 2024).

DIN 10557558
Primary Designation Director
First Appointment 20 Mar 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Drug Dash Medtech Private Limited U47912KL2024PTC086766
Director20 Mar 20242024Active

Board colleagues of Akhila Narayan Nambilithodi Ponnumani

NameDINCompanyDesignation
Pranoy Kelikodan09507010Drug Dash Medtech Private LimitedDirector

Directorship timeline

Open interactive timeline →
Drug Dash Medtech Private Limited
Premium access

Shareholding and investment profile for Akhila Narayan Nambilithodi Ponnumani

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Akhila Narayan Nambilithodi Ponnumani

Akhila Narayan Nambilithodi Ponnumani currently holds 1 directorship: Drug Dash Medtech Private Limited (Director, since 20 Mar 2024).

Akhila Narayan Nambilithodi Ponnumani was first appointed on 20 Mar 2024 as Director at Drug Dash Medtech Private Limited.

The current boards of Akhila Narayan Nambilithodi Ponnumani's companies include Pranoy Kelikodan (Drug Dash Medtech Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available